Vis enkel innførsel

dc.contributor.authorKimball, Alexandra Boer
dc.contributor.authorTzellos, Thrasyvoulos
dc.contributor.authorCalimlim, Brian M
dc.contributor.authorTeixeira, Henrique D
dc.contributor.authorGeng, Ziqian
dc.contributor.authorOkun, Martin M
dc.date.accessioned2019-03-08T08:24:51Z
dc.date.available2019-03-08T08:24:51Z
dc.date.issued2018-08-07
dc.description.abstractHidradenitis Suppurativa Clinical Response (HiSCR), is a validated tool that has been used to assess the efficacy of adalimumab among patients with hidradenitis suppurativa. We evaluated the clinical meaning of HiSCR by relating it to patient-reported outcomes to give further context to its achievement in a post hoc analysis of integrated data from two phase 3 clinical trials (PIONEER I and II). Pooling placebo and active treatment arms, 39% of patients (245/629) achieved HiSCR at week 12. Irrespective of treatment, significantly (p < 0.05) more HiSCR responders than non-responders experienced clinically meaningful improvement in Dermatology Life Quality Index (60.5% vs 30.4%), Pain Numeric Rating Scale (46.9% vs 19.9%), hidradenitis suppurativa quality of life (49.4% vs 26.9%), work-related performance (52.6% vs 37.7%), and non-work-related performance (59.5% vs 33.3%). Clinically meaningful outcomes in hidradenitis suppurativa are more likely to be attained in patients achieving HiSCR level improvement.en_US
dc.description.sponsorshipAbbVieen_US
dc.descriptionSource at <a href=https://doi.org/10.2340/00015555-3012> https://doi.org/10.2340/00015555-3012</a>.en_US
dc.identifier.citationKimball, A.B., Tzellos, T., Calimlim, B.M., Teixeira, H.D., Geng, Z. & Okun, M.M. (2018). Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: <i>Post hoc</i> analysis of pooled data from PIONEER I and II. <i>Acta Dermato-Venereologica, 98</i>(10), 932-937. https://doi.org/10.2340/00015555-3012en_US
dc.identifier.cristinIDFRIDAID 1645750
dc.identifier.doi10.2340/00015555-3012
dc.identifier.issn0001-5555
dc.identifier.issn1651-2057
dc.identifier.urihttps://hdl.handle.net/10037/14901
dc.language.isoengen_US
dc.publisherSociety for Publication of Acta Dermato-Venereologicaen_US
dc.relation.journalActa Dermato-Venereologica
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Dermatology and venereology: 753en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Dermatologi og venerologi: 753en_US
dc.subjectabscessen_US
dc.subjectinflammatory noduleen_US
dc.subjectDLQIen_US
dc.subjectPIONEER Ien_US
dc.subjectPIONEER IIen_US
dc.subjectminimum clinically important differenceen_US
dc.titleAchieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: Post hoc analysis of pooled data from PIONEER I and IIen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel